Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as zodasiran Injection, Zodasiran
ARO-ANG3 · 4 trials · 5 indications
| Arm | Type | Description |
|---|---|---|
| Zodasiran | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | Calculated volume to match active treatment by sc injection (randomized period). 4 or 5 doses of zodasiran by sc injection (optional open-label period) |
| ARO-ANG3 50 mg | EXPERIMENTAL | Two doses of ARO-ANG3 by subcutaneous (sc) injection at Day 1 and Week 12 during double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period. |
| ARO-ANG3 100 mg | EXPERIMENTAL | Two doses of ARO-ANG3 bysc injection at Day 1 and Week 12 during double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period. |
| ARO-ANG3 200 mg | EXPERIMENTAL | Two doses of ARO-ANG3 by sc injection at Day 1 and Week 12 during double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period. |
| ARO-ANG3 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Zodasiran | DRUG | By sc injection |
| zodasiran Injection | DRUG | ARO-ANG3 Injection |
| Placebo | DRUG | sterile normal saline (0.9% NaCl) |
| ARO-ANG3 | DRUG | ARO-ANG3 Injection |
| sterile normal saline (0.9% NaCl) | DRUG | calculated volume to match active treatment |
Inclusion Criteria: * Adolescents 12 to \<18 years of age who are nonpregnant, nonlactating, and do not plan to become pregnant during the study * Body weight ≥35 kilograms (kg) at screening * HoFH based on a supportive genetic test (from a source-verifiable medical record or based on screening gen...
ARO-ANG3 is an investigational drug being developed for the treatment of dyslipidemias, including mixed dyslipidemia, familial hypercholesterolemia, and hypertriglyceridemia. It is designed to address abnormal levels of lipids in the blood, which are risk factors for cardiovascular disease.
ARO-ANG3 is being developed by Arrowhead Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol ARWR. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational therapy.
ARO-ANG3 is currently in clinical development. It has completed a Phase 1 trial and a Phase 2 trial. The drug is not yet approved by regulatory authorities and remains investigational, meaning it is still being studied for safety and effectiveness.
ARO-ANG3 has been studied in two completed clinical trials. The first, NCT03747224, was a Phase 1 study in healthy volunteers and patients with dyslipidemias, familial hypercholesterolemia, or hypertriglyceridemia. The second, NCT04832971, was a Phase 2 study in adults with mixed dyslipidemia.
ARO-ANG3 is the primary name for this investigational drug. No alternative names have been reported for this asset. It is distinct from other drugs in development and is identified by its unique code, ARO-ANG3.